1. In vitro and in vivo characterization of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonist;Kudlacz;J. Pharmacol. Exp. Ther.,1996
2. SSR240600 [(R)-2-(1-{2-[4-{2-[3,5-Bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl}- 4-piperidinyl)-2-methylpropanamide], a Centrally Active Nonpeptide Antagonist of the Tachykinin Neurokinin-1 Receptor: I. Biochemical and Pharmacological Characterization
3. Identification of both NK1 and NK2 receptors in guinea-pig airways;McKee;Br. J. Pharmacol.,1993
4. Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret;Tsuchiya;Pharmacology,2002
5. Pharmacological characterization of LY303870: A novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist;Gitter;J. Pharmacol. Exp. Ther.,1995